Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients
IntroductionUrine samples are non-invasive approaches to study potential circulating biomarkers from the host organism. Specific proteins cross the bloodstream through the intestinal barrier and may also derive from gut microbiota. In this study, we aimed to evaluate the predictive role of the host...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1543817/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850184000632520704 |
|---|---|
| author | David Dora Peter Revisnyei Peter Revisnyei Alija Pasic Gabriella Galffy Edit Dulka Anna Mihucz Brigitta Roskó Sara Szincsak Anton Iliuk Glen J. Weiss Zoltan Lohinai Zoltan Lohinai |
| author_facet | David Dora Peter Revisnyei Peter Revisnyei Alija Pasic Gabriella Galffy Edit Dulka Anna Mihucz Brigitta Roskó Sara Szincsak Anton Iliuk Glen J. Weiss Zoltan Lohinai Zoltan Lohinai |
| author_sort | David Dora |
| collection | DOAJ |
| description | IntroductionUrine samples are non-invasive approaches to study potential circulating biomarkers from the host organism. Specific proteins cross the bloodstream through the intestinal barrier and may also derive from gut microbiota. In this study, we aimed to evaluate the predictive role of the host and bacterial urine extracellular vesicle (EV) proteomes in patients with non-small cell lung cancer (NSCLC) treated with anti-PD1 immunotherapy.MethodsWe analyzed the urine EV proteome of 33 advanced-stage NSCLC patients treated with anti-PD1 immunotherapy with LC-MS/MS, stratifying patients according to long (>6 months) and short (≤6 months) progression-free survival (PFS). Gut microbial communities on a subcohort of 23 patients were also analyzed with shotgun metagenomics. Internal validation was performed using the Random Forest (RF) machine learning (ML) algorithm. RF was validated with a non-linear Bayesian ML model. Gene enrichment, and pathway analysis of host urine proteins were analyzed using the Reactome and Gene Ontology databases.ResultsWe identified human (n=3513), bacterial (n=2647), fungal (n=19), and viral (n=4) proteins. 186 human proteins showed differential abundance (p<0.05) according to PFS groups, 101 being significantly more abundant in patients with short PFS and n=85 in patients with long PFS. We found several pathways that were significantly enriched in patients with short PFS (vs long PFS). Multivariate Cox regression showed that human urine proteins MPP5, IGKV6-21, NT5E, and KRT27 were strongly associated with long PFS, and LMAN2, NUTF2, NID1, TNC, IGF1, BCR, GPHN, and PPBP showed the strongest association with short PFS. We revealed that an increased bacterial/host protein ratio in the urine is more frequent in patients with long PFS. Increased abundance of E. coli and E. faecalis proteins in the urine positively correlates with their gut metagenomic abundance. RF ML model supported the reliability in predicting PFS for critical human urine proteins (AUC=0.89), accuracy (95%) and Bacterial proteins (AUC=0.74).ConclusionTo our knowledge, this is the first study to depict the predictive role of the host and bacterial urine proteome in anti-PD1-treated advanced NSCLC. |
| format | Article |
| id | doaj-art-be67293a5d7c4775b61af9a464ee4752 |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-be67293a5d7c4775b61af9a464ee47522025-08-20T02:17:09ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-04-011610.3389/fimmu.2025.15438171543817Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patientsDavid Dora0Peter Revisnyei1Peter Revisnyei2Alija Pasic3Gabriella Galffy4Edit Dulka5Anna Mihucz6Brigitta Roskó7Sara Szincsak8Anton Iliuk9Glen J. Weiss10Zoltan Lohinai11Zoltan Lohinai12Department of Anatomy, Histology and Embryology, Semmelweis University, Budapest, HungaryDepartment of Telecommunications and Media Informatics, Budapest University of Technology and Economics, Budapest, HungaryHUN-REN-BME Information Systems Research Group, Budapest, HungaryDepartment of Telecommunications and Media Informatics, Budapest University of Technology and Economics, Budapest, HungaryCounty Hospital of Torokbalint, Torokbalint, HungaryCounty Hospital of Torokbalint, Torokbalint, HungaryDepartment of Anatomy, Histology and Embryology, Semmelweis University, Budapest, HungaryDepartment of Anatomy, Histology and Embryology, Semmelweis University, Budapest, HungaryTranslational Medicine Institute, Semmelweis University, Budapest, HungaryTymora Analytical Operations, West Lafayette, IN, United StatesDepartment of Medicine, UMass Chan Medical School, Worcester, MA, United StatesTranslational Medicine Institute, Semmelweis University, Budapest, HungaryCounty Hospital of Torokbalint, Torokbalint, HungaryIntroductionUrine samples are non-invasive approaches to study potential circulating biomarkers from the host organism. Specific proteins cross the bloodstream through the intestinal barrier and may also derive from gut microbiota. In this study, we aimed to evaluate the predictive role of the host and bacterial urine extracellular vesicle (EV) proteomes in patients with non-small cell lung cancer (NSCLC) treated with anti-PD1 immunotherapy.MethodsWe analyzed the urine EV proteome of 33 advanced-stage NSCLC patients treated with anti-PD1 immunotherapy with LC-MS/MS, stratifying patients according to long (>6 months) and short (≤6 months) progression-free survival (PFS). Gut microbial communities on a subcohort of 23 patients were also analyzed with shotgun metagenomics. Internal validation was performed using the Random Forest (RF) machine learning (ML) algorithm. RF was validated with a non-linear Bayesian ML model. Gene enrichment, and pathway analysis of host urine proteins were analyzed using the Reactome and Gene Ontology databases.ResultsWe identified human (n=3513), bacterial (n=2647), fungal (n=19), and viral (n=4) proteins. 186 human proteins showed differential abundance (p<0.05) according to PFS groups, 101 being significantly more abundant in patients with short PFS and n=85 in patients with long PFS. We found several pathways that were significantly enriched in patients with short PFS (vs long PFS). Multivariate Cox regression showed that human urine proteins MPP5, IGKV6-21, NT5E, and KRT27 were strongly associated with long PFS, and LMAN2, NUTF2, NID1, TNC, IGF1, BCR, GPHN, and PPBP showed the strongest association with short PFS. We revealed that an increased bacterial/host protein ratio in the urine is more frequent in patients with long PFS. Increased abundance of E. coli and E. faecalis proteins in the urine positively correlates with their gut metagenomic abundance. RF ML model supported the reliability in predicting PFS for critical human urine proteins (AUC=0.89), accuracy (95%) and Bacterial proteins (AUC=0.74).ConclusionTo our knowledge, this is the first study to depict the predictive role of the host and bacterial urine proteome in anti-PD1-treated advanced NSCLC.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1543817/fullNSCLCimmunotherapygut microbiomeEV proteinurine proteomemachine learning |
| spellingShingle | David Dora Peter Revisnyei Peter Revisnyei Alija Pasic Gabriella Galffy Edit Dulka Anna Mihucz Brigitta Roskó Sara Szincsak Anton Iliuk Glen J. Weiss Zoltan Lohinai Zoltan Lohinai Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients Frontiers in Immunology NSCLC immunotherapy gut microbiome EV protein urine proteome machine learning |
| title | Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients |
| title_full | Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients |
| title_fullStr | Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients |
| title_full_unstemmed | Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients |
| title_short | Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients |
| title_sort | host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non small cell lung cancer patients |
| topic | NSCLC immunotherapy gut microbiome EV protein urine proteome machine learning |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1543817/full |
| work_keys_str_mv | AT daviddora hostandbacterialurineproteomicsmightpredicttreatmentoutcomesforimmunotherapyinadvancednonsmallcelllungcancerpatients AT peterrevisnyei hostandbacterialurineproteomicsmightpredicttreatmentoutcomesforimmunotherapyinadvancednonsmallcelllungcancerpatients AT peterrevisnyei hostandbacterialurineproteomicsmightpredicttreatmentoutcomesforimmunotherapyinadvancednonsmallcelllungcancerpatients AT alijapasic hostandbacterialurineproteomicsmightpredicttreatmentoutcomesforimmunotherapyinadvancednonsmallcelllungcancerpatients AT gabriellagalffy hostandbacterialurineproteomicsmightpredicttreatmentoutcomesforimmunotherapyinadvancednonsmallcelllungcancerpatients AT editdulka hostandbacterialurineproteomicsmightpredicttreatmentoutcomesforimmunotherapyinadvancednonsmallcelllungcancerpatients AT annamihucz hostandbacterialurineproteomicsmightpredicttreatmentoutcomesforimmunotherapyinadvancednonsmallcelllungcancerpatients AT brigittarosko hostandbacterialurineproteomicsmightpredicttreatmentoutcomesforimmunotherapyinadvancednonsmallcelllungcancerpatients AT saraszincsak hostandbacterialurineproteomicsmightpredicttreatmentoutcomesforimmunotherapyinadvancednonsmallcelllungcancerpatients AT antoniliuk hostandbacterialurineproteomicsmightpredicttreatmentoutcomesforimmunotherapyinadvancednonsmallcelllungcancerpatients AT glenjweiss hostandbacterialurineproteomicsmightpredicttreatmentoutcomesforimmunotherapyinadvancednonsmallcelllungcancerpatients AT zoltanlohinai hostandbacterialurineproteomicsmightpredicttreatmentoutcomesforimmunotherapyinadvancednonsmallcelllungcancerpatients AT zoltanlohinai hostandbacterialurineproteomicsmightpredicttreatmentoutcomesforimmunotherapyinadvancednonsmallcelllungcancerpatients |